^
    3d
    Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers (clinicaltrials.gov)
    P1, N=162, Recruiting, Novartis Pharmaceuticals | N=124 --> 162 | Trial completion date: Jun 2030 --> Jan 2031 | Trial primary completion date: Jun 2030 --> Jan 2031
    Enrollment change • Trial completion date • Trial primary completion date
    5d
    FAPI-PETCD: 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease (clinicaltrials.gov)
    P1, N=45, Not yet recruiting, Mayo Clinic
    New P1 trial
    6d
    Exploratory Analysis of [68Ga]Ga-FAP-2286 PET/CT Quantitative Parameters for Predicting Response to [177Lu]Lu-FAP-2286 Therapy in Non-small Cell Lung Cancer. (PubMed, Clin Nucl Med)
    Quantitative parameters derived from [68Ga]Ga-FAP-2286 PET/CT are valuable predictors of [177Lu]Lu-FAP-2286 treatment efficacy in NSCLC patients. Dynamic monitoring of these metrics allows for early identification of treatment responses and supports personalized therapy strategies.
    Journal
    |
    FAP (Fibroblast activation protein, alpha)
    |
    lutetium Lu 177 rofapitide tetraxetan (AAA614)
    9d
    Linker-Driven Breakthrough: Design of a Novel Linker for Enhanced Theranostic Performance of FAPI Trimer. (PubMed, J Med Chem)
    Moreover, 177Lu-DOTA-FAPI-FUSCC-Tri highlights its potential as a dual-purpose agent for the integrated diagnosis and treatment of FAP-expressing tumors. This study identified a novel FAP trimer linker and successfully developed a high-performance FAP trimer based on it.
    Journal • Breakthrough therapy
    |
    FAP (Fibroblast activation protein, alpha)
    16d
    Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) (clinicaltrials.gov)
    P2, N=35, Recruiting, Institut Curie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    177Lu-LNC1004
    18d
    ATLAS: Actinium Therapy for Late-stage Aggressive Sarcomas (clinicaltrials.gov)
    P1, N=26, Recruiting, Ratio Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    27d
    A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    gemcitabine • paclitaxel • AiRuiLi (adebrelimab) • SHR-7367
    1m
    The allogeneic FAP-CAR-IL15 iNKT therapy MiNK-215 remodels the tumor stroma to enhance antitumor immunity. (PubMed, Cancer Immunol Res)
    In a lung tumor mouse model, MiNK-215 depleted FAP+ CAFs, enhanced antigen-specific T-cell infiltration, and promoted durable antitumor immunity without off-target toxicity. These findings were extended to human organoid models of treatment-refractory Microsatellite Stable Colorectal Cancer (MSS-CRC) liver metastases, establishing FAP-CAR-IL-15 iNKT cells as a promising strategy to overcome immunotherapy resistance in solid tumors.
    Journal
    |
    FAP (Fibroblast activation protein, alpha) • IL15 (Interleukin 15)
    1m
    A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=160, Recruiting, Boehringer Ingelheim | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2027 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ezabenlimab (BI 754091) • BI 765179
    1m
    Squaric-acid-engineered FAP2286: A next-generation 68Ga/177Lu theranostic ligand with synergistically enhanced affinity, hydrophilicity, and tumor retention. (PubMed, Bioorg Chem)
    Squaric acid derivatization synergistically elevates affinity, hydrophilicity, and intratumoral residence while preserving safety, establishing 68Ga/177Lu-FAP2286-SA as a clinically translatable, next-generation theranostic pair for FAP-positive malignancies.
    Journal
    |
    FAP (Fibroblast activation protein, alpha)
    |
    lutetium Lu 177 rofapitide tetraxetan (AAA614)
    2ms
    BXCL701-201: A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. (clinicaltrials.gov)
    P1/2, N=98, Completed, BioXcel Therapeutics Inc | Active, not recruiting --> Completed | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2025 --> Dec 2024
    Trial completion • Phase classification • Trial completion date
    |
    Keytruda (pembrolizumab) • talabostat (BXCL701)
    2ms
    Synthesis and Evaluation of Novel 99mTc-Labeled Fibroblast Activation Protein Inhibitors Containing Cyclohexane as Promising Tumor Tracers. (PubMed, Mol Pharm)
    SPECT/CT imaging revealed obvious uptake in tumors with high FAP expression (U87MG, HT-1080-FAP and HT-29) with a clean background, and no visualization was observed in the tumors of the blocking group (U87MG block, HT-1080-FAP block and HT-29 block) or the tumors with low FAP expression (HT-1080), indicating that the uptake of [99mTc]Tc-(tricine/TPPTS)-L in the tumors had high FAP specificity. Therefore, [99mTc]Tc-(tricine/TPPTS)-L is expected to become a potential tumor molecular probe for clinical application.
    Journal
    |
    FAP (Fibroblast activation protein, alpha)